---
title: 'Regulatory Daily Summary: What Happened on November 18, 2026'
headline: FDA rejects Summit’s ivonescimab application over questions about U.S. benefit
description: The European Commission authorized Revolution Medicines’ Rasonque for
  previously treated pancreatic cancer, while the White House withdrew its FDA chief
  nominee.
url: https://thebench.bio/news/regulatory/2026-11-18
topic: regulatory
date: '2026-11-18'
covers:
- '2026-11-18'
date_published: '2026-11-18T12:03:26Z'
date_modified: '2026-11-18T12:03:26Z'
tags:
- Regulatory
- Industry
sources: 6
publisher: TheBench.Bio
---

# Regulatory Daily Summary: What Happened on November 18, 2026

**FDA rejects Summit’s ivonescimab application over questions about U.S. benefit**

The European Commission authorized Revolution Medicines’ Rasonque for previously treated pancreatic cancer, while the White House withdrew its FDA chief nominee.

## Today in brief

The FDA turned down Summit Therapeutics’ U.S. application for ivonescimab, saying it could not establish that the drug’s benefit extended to U.S. patients. [1] [2] The European Commission cleared Rasonque for some adults with metastatic pancreatic cancer after at least one systemic treatment. [3]

The White House pulled Heidi Overton’s nomination to lead the FDA. [4] The UK regulator is building an early-support service for medicines developers, and GSK gained a second cancer drug approval tied to its Nuvalent acquisition. [5] [6]

## FDA rejects Summit’s ivonescimab application

The FDA sent Summit Therapeutics a complete response letter, declining its first U.S. application for ivonescimab. [2] The letter, made public November 17, said the agency could not establish whether HARMONi’s benefit applied to U.S. patients. [1]

HARMONi met its progression-free survival endpoint, a measure of how long patients live without their cancer worsening, but missed its overall survival endpoint. [2] The FDA had indicated that improved overall survival would be needed to approve the drug for previously treated EGFR-mutant lung cancer. [2] Patients in North America and Europe made up 38% of enrollment, but patients in China accounted for 93% of progression-free survival events in the primary analysis. [1]

## EU authorizes Rasonque for previously treated pancreatic cancer

The European Commission authorized Revolution Medicines’ Rasonque for adults with metastatic pancreatic adenocarcinoma who have received at least one systemic treatment. [3] The approval permits once-daily oral treatment whether or not a tumor has an identified RAS mutation, and applies in EU member states, Liechtenstein, Iceland and Norway. [3]

The decision came after a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use and an expedited phased review. [3] In the global Phase III RASolute 302 trial, Rasonque met its primary and key secondary endpoints in both the overall study population and the subgroup with RAS G12 mutations. [3] Patient access will depend on national pricing, health technology assessment and reimbursement processes. [3]

## Also worth knowing

- The MHRA received funding from the Office for Life Sciences to develop and test AdvanceGxP, an early regulatory and quality support service initially focused on advanced medicines manufacturing. The agency announced the service on November 17. [5]
- GSK received a second cancer drug approval associated with its acquisition of Nuvalent. [6]

## The day in numbers

- **93%**: Share of HARMONi’s progression-free survival events in the primary analysis that came from patients in China. [1]
- **38%**: Share of HARMONi patients enrolled in North America or Europe. [1]

## Also published

- [Simplified regulatory pathways are key for the future of biosimilars in Europe](<https://www.clinicaltrialsarena.com/features/simplified-regulatory-pathways-are-key-for-the-future-of-biosimilars-in-europe/>), Clinical Trials Arena

## Sources

1. [Summit setback reinforces FDA pushback on China-heavy data](<https://www.biocentury.com/article/661656/summit-setback-reinforces-fda-pushback-on-china-heavy-data?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-18
2. [FDA holds Summit to survival bar in ivonescimab CRL](<https://www.biocentury.com/article/661634/fda-holds-summit-to-survival-bar-in-ivonescimab-crl?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-17
3. [Revolution Medicines’ Rasonque gains EC authorisation for pancreatic cancer](<https://www.pharmaceutical-technology.com/news/revolution-medicines-rasonque-ec-pancreatic-cancer/>), Pharmaceutical Technology, 2026-11-18
4. [White House drops Heidi Overton pick for FDA chief](<https://pharmaphorum.com/news/white-house-drops-heidi-overton-pick-fda-chief>), pharmaphorum, 2026-11-18
5. [New MHRA service to support medicines innovation and strengthen UK manufacturing  ](<https://www.gov.uk/government/news/new-mhra-service-to-support-medicines-innovation-and-strengthen-uk-manufacturing>), MHRA, 2026-11-18
6. [GSK gets second cancer drug approval from Nuvalent buy](<https://pharmaphorum.com/news/gsk-gets-second-cancer-drug-approval-nuvalent-buy>), pharmaphorum, 2026-11-18

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biocentury.com/article/661656/summit-setback-reinforces-fda-pushback-on-china-heavy-data?utm_source=bc_rss&utm_medium=rss>
[2]: <https://www.biocentury.com/article/661634/fda-holds-summit-to-survival-bar-in-ivonescimab-crl?utm_source=bc_rss&utm_medium=rss>
[3]: <https://www.pharmaceutical-technology.com/news/revolution-medicines-rasonque-ec-pancreatic-cancer/>
[4]: <https://pharmaphorum.com/news/white-house-drops-heidi-overton-pick-fda-chief>
[5]: <https://www.gov.uk/government/news/new-mhra-service-to-support-medicines-innovation-and-strengthen-uk-manufacturing>
[6]: <https://pharmaphorum.com/news/gsk-gets-second-cancer-drug-approval-nuvalent-buy>
